Akebia Ther (AKBA NASDAQ) stock market data APIs
$2.9484
-0.01(-0.3%)
as of September 15, 2025
Try our APIs with
free plan!
Akebia Ther Financial Data Overview
Price chart is built with
Anychart
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Prev. Close
2.9484
Open
2.9404
High
3.0193
Low
2.9484
52 wk Range
1.24-4.0787
Market Cap
782 M
Shares Outstanding
265 M
Revenue
204 M
EPS
0.0267
Beta
1.024
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Akebia Ther (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Akebia Ther data using free add-ons & libraries
Get Akebia Ther Fundamental Data
Akebia Ther Fundamental data includes:
- Net Revenue: 204 M
- EBITDA: 23 348 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Akebia Ther News
New
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease...
Akebia Therapeutics (AKBA) Bounces to Profitability amid Kidney Treatment Growth
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best multibagger penny stocks to buy according to analysts. On August 7, the company delivered its second-quarter results, which showed strong mom...
Akebia outlines access to over 275,000 dialysis patients for Vafseo in Q4 as DaVita pilot launches
Earnings Call Insights: Akebia Therapeutics (AKBA) Q2 2025 MANAGEMENT VIEW * John P. Butler, CEO, reported that "we generated over $13 million in Vafseo revenue in Q2 with approximately $12 millio...
Akebia GAAP EPS of $0.00 beats by $0.02, revenue of $62.47M beats by $15.23M
* Akebia press release [https://seekingalpha.com/pr/20192771-akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business] (NASDAQ:AKBA [https://seekingalpha.com/symbol/AKBA...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
